Torrent Pharma third quarter net profit up 18% at Rs 297 crore

The firm reported an 18.32 per cent rise in its consolidated net profit to Rs 297 crore for the quarter ended in December.

pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing
Representational image
Press Trust of India New Delhi
2 min read Last Updated : Feb 08 2021 | 5:40 PM IST

Drug firm Torrent Pharmaceuticals on Monday reported an 18.32 per cent rise in its consolidated net profit to Rs 297 crore for the quarter ended in December.

The company had posted a net profit of Rs 251 crore for the corresponding period of the previous fiscal, Torrent Pharma said in a filing to BSE.

Consolidated revenue of the company stood at Rs 1,995 crore for the quarter under consideration. It was Rs 1,966 crore for the same period a year ago, it added.

India revenues for the third quarter ended December 2020 was at Rs 930 crore, a growth of 7 per cent. Growth was driven by market recovery, continued momentum in chronic brands and strong recovery in sub-chronic brands, Torrent Pharma said.

US revenues at Rs 292 crore, were down by 24 per cent. Sales were impacted by price erosion on base business and base impact of Sartan portfolio discontinuation, it added.

Brazil revenues at Rs 173 crore, were down 8 per cent for the quarter under consideration. Germany revenues were up 21 per cent to Rs 265 crore for the quarter under consideration, the filing said.

The board of the company has approved an interim dividend of Rs 20 per equity share of Rs 5 fully paid up, it added.

Shares of Torrent Pharmaceuticals closed at Rs 2,758.30 per scrip on the BSE, up 0.25 per cent from its previous close.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Torrent PharmaTorrent Pharma resultsQ3 resultsPharma sector

First Published: Feb 08 2021 | 5:38 PM IST

Next Story